Navigation Links
W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Date:4/7/2008

AURORA, ON, April 7 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX: HBP / Frankfurt: WKN 918864)

Helix BioPharma Corp. today announced that the board of directors has increased the authorized number of directors from six to seven and has appointed Mr. W. Thomas Hodgson as director to fill the newly created position. Mr. Hodgson will also serve as chair of the three member Audit Committee, replacing Mr. Jack Kay who previously held the position.

Mr. Hodgson is currently senior partner and chairman of Greenbrook Capital Partners and acts as an advisor to the chairman of Magna Entertainment Corp. Mr. Hodgson's prior roles include senior positions with Canadian financial institutions and U.K. based companies.

Donald Segal, chief executive officer of Helix BioPharma, said, "Tom's diverse professional background and capital markets experience will be an invaluable resource to the board. In addition, his extensive knowledge of complex financial matters makes him ideally suited to chair our audit committee. We look forward to his contributions."

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP" and quoted on the Frankfurt, Berlin, Munich and Stuttgart Stock Exchanges under the same symbol.

The Toronto Stock Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of the content of this News

Release.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists
2. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
3. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
4. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
5. Neurocrine Biosciences to Present at the Thomas Weisel Partners Healthcare Conference
6. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
7. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
8. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
9. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
10. Cepheid to Present at Thomas Weisel Partners Healthcare Conference
11. Luminex Corporation to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the ... technology, today announced that it has been named to The Silicon Review’s “20 Fastest ... and other markets, Cambridge Semantics serves the needs of end users facing some of ...
(Date:4/27/2016)... ... April 27, 2016 , ... Most consumers engage with biometrics ... for secure access, voice recognition for hands-free communication, and facial recognition to help ... biometrics technology today. But if they asked Joey Pritikin, Vice President of ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Board of Directors ... of John Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from Alexion ... commercial leaders responsible for the commercialization of multiple orphan drug indications. Mr. ...
(Date:4/27/2016)... ... April 27, 2016 , ... A compact PET scanner ... and MRI (Magnetic Resonance Imaging) in existing third-party MRI systems. PET and MRI ... small animal subjects. Simultaneous PET/MRI imaging offers a solution to many challenges that ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):